Literature DB >> 18175337

Placebo influences on dyskinesia in Parkinson's disease.

Christopher G Goetz1, Eugene Laska, Christine Hicking, Philippe Damier, Thomas Müller, John Nutt, C Warren Olanow, Olivier Rascol, Hermann Russ.   

Abstract

Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placebo-associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical design comparing sarizotan to placebo for treating dyskinesia were accessed. Sarizotan (2 mg/day) failed to improve dyskinesia compared with placebo, but both treatments improved dyskinesia compared with baseline. Stepwise regression identified baseline characteristics that influenced dyskinesia response to placebo, and these factors were entered into a logistic regression model to quantify their influence on placebo-related dyskinesia improvements and worsening. Because placebo-associated improvements in Parkinsonism have been attributed to heightened dopaminergic activity, we also examined the association between changes in Parkinsonism and dyskinesia. Four hundred eighty-four subjects received placebo treatment; 178 met criteria for placebo-associated dyskinesia improvement and 37 for dyskinesia worsening. Older age, lower baseline Parkinsonism score, and lower total daily levodopa doses were associated with placebo-associated improvement, whereas lower baseline dyskinesia score was associated with placebo-associated worsening. Placebo-associated dyskinesia changes were not correlated with Parkinsonism changes, and all effects in the sarizotan group were statistically explained by the placebo-effect regression model. Dyskinesias are affected by placebo treatment. The absence of correlation between placebo-induced changes in dyskinesia and Parkinsonism argues against a dopaminergic activation mechanism to explain placebo-associated improvements in dyskinesia. The magnitude and variance of placebo-related changes and the factors that influence them can be helpful in the design of future clinical trials of antidyskinetic agents. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175337      PMCID: PMC2689363          DOI: 10.1002/mds.21897

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

1.  Objective changes in motor function during placebo treatment in PD.

Authors:  C G Goetz; S Leurgans; R Raman; G T Stebbins
Journal:  Neurology       Date:  2000-02-08       Impact factor: 9.910

Review 2.  The placebo effect in neurological disorders.

Authors:  Raúl de la Fuente-Fernández; Michael Schulzer; A Jon Stoessl
Journal:  Lancet Neurol       Date:  2002-06       Impact factor: 44.182

3.  Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Authors:  C Warren Olanow; Philippe Damier; Christopher G Goetz; Thomas Mueller; John Nutt; Olivier Rascol; Alexandru Serbanescu; Frieda Deckers; Hermann Russ
Journal:  Clin Neuropharmacol       Date:  2004 Mar-Apr       Impact factor: 1.592

Review 4.  The nocebo phenomenon: concept, evidence, and implications for public health.

Authors:  R A Hahn
Journal:  Prev Med       Date:  1997 Sep-Oct       Impact factor: 4.018

5.  Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.

Authors:  R de la Fuente-Fernández; T J Ruth; V Sossi; M Schulzer; D B Calne; A J Stoessl
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

6.  Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.

Authors:  Christopher G Goetz; Sue Leurgans; Rema Raman
Journal:  Mov Disord       Date:  2002-03       Impact factor: 10.338

Review 7.  Glutamatergic transmission in opiate and alcohol dependence.

Authors:  George Robert Siggins; Gilles Martin; Marisa Roberto; Zhiguo Nie; Samuel Madamba; Luis De Lecea
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

8.  Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus.

Authors:  Fabrizio Benedetti; Luana Colloca; Elena Torre; Michele Lanotte; Antonio Melcarne; Marina Pesare; Bruno Bergamasco; Leonardo Lopiano
Journal:  Nat Neurosci       Date:  2004-05-16       Impact factor: 24.884

9.  Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.

Authors:  Christopher G Goetz; Joanne Wuu; Michael P McDermott; Charles H Adler; Stanley Fahn; Curt R Freed; Robert A Hauser; Warren C Olanow; Ira Shoulson; P K Tandon; Sue Leurgans
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

10.  Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.

Authors:  Barbara Picconi; Diego Centonze; Kerstin Håkansson; Giorgio Bernardi; Paul Greengard; Gilberto Fisone; M Angela Cenci; Paolo Calabresi
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

View more
  26 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.

Authors:  Bijan D Ghaffari; Benzi Kluger
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

Review 3.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 4.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

5.  Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.

Authors:  Gesine Paul; Olof Zachrisson; Andrea Varrone; Per Almqvist; Markus Jerling; Göran Lind; Stig Rehncrona; Bengt Linderoth; Hjalmar Bjartmarz; Lisa L Shafer; Robert Coffey; Mikael Svensson; Katarina Jansson Mercer; Anton Forsberg; Christer Halldin; Per Svenningsson; Håkan Widner; Jonas Frisén; Sven Pålhagen; Anders Haegerstrand
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

Review 6.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

7.  Teaching neurons to respond to placebos.

Authors:  Fabrizio Benedetti; Elisa Frisaldi; Elisa Carlino; Lucia Giudetti; Alan Pampallona; Maurizio Zibetti; Michele Lanotte; Leonardo Lopiano
Journal:  J Physiol       Date:  2016-02-24       Impact factor: 5.182

Review 8.  Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicine.

Authors:  Katja Weimer; Luana Colloca; Paul Enck
Journal:  Gerontology       Date:  2015       Impact factor: 5.140

9.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

Review 10.  Non-dopaminergic treatments for motor control in Parkinson's disease.

Authors:  Susan H Fox
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.